1. Banerji, Christopher R S. . PAX7 target gene repression associates with FSHD progression and pathology over 1 year. In Human molecular genetics, 29, 2124-2133. doi:10.1093/hmg/ddaa079. https://pubmed.ncbi.nlm.nih.gov/32347924/
2. Quinelato, Valquiria, Bonato, Letícia Ladeira, Vieira, Alexandre Rezende, Calasans-Maia, Jose Albuquerque, Tesch, Ricardo. 2021. PAX7 gene polymorphism in muscular temporomandibular disorders as potentially related to muscle stem cells. In BMC musculoskeletal disorders, 22, 959. doi:10.1186/s12891-021-04846-w. https://pubmed.ncbi.nlm.nih.gov/34789211/
3. Banerji, Christopher R S, Zammit, Peter S. . PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level. In Human molecular genetics, 28, 2224-2236. doi:10.1093/hmg/ddz043. https://pubmed.ncbi.nlm.nih.gov/31067297/
4. Bhele, Sanica, Chrisinger, John S A, Farrell, Nyssa Fox, Raptis, Constantine A, Chernock, Rebecca D. 2023. Biphenotypic Sinonasal Sarcoma with a Novel PAX7::PPARGC1 Fusion: Expanding the Spectrum of Gene Fusions Beyond the PAX3 Gene. In Head and neck pathology, 17, 826-831. doi:10.1007/s12105-023-01566-6. https://pubmed.ncbi.nlm.nih.gov/37378830/
5. Mansouri, A. . The role of Pax3 and Pax7 in development and cancer. In Critical reviews in oncogenesis, 9, 141-9. doi:. https://pubmed.ncbi.nlm.nih.gov/9973247/
6. Sincennes, Marie-Claude, Brun, Caroline E, Lin, Alexander Y T, Kawabe, Yoh-Ichi, Rudnicki, Michael A. 2021. Acetylation of PAX7 controls muscle stem cell self-renewal and differentiation potential in mice. In Nature communications, 12, 3253. doi:10.1038/s41467-021-23577-z. https://pubmed.ncbi.nlm.nih.gov/34059674/
智鼠故事 
